Delcath Systems, Inc. (DCTH) Stock Analysis and Metrics

Delcath Systems

NASDAQ: DCTH

$12.23 ▼ -0.20 (-1.61%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap16,569.19

P/E856.11

P/S0.00

Div. Yield0.00

Revenue Growth (1y) (Qtr)26.33

Add ratio to table…

About

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver. The company's lead product, the HEPZATO KIT, is a drug/device combination that received FDA approval in August 2023 for adult patients with uveal melanoma liver metastases. In Europe, the company markets the CHEMOSAT hepatic delivery system, a device used to deliver melphalan to the liver during percutaneous hepatic perfusion procedures. These products enable high dose chemotherapy delivery to the liver while limiting systemic exposure.

Delcath Systems, Inc. generates revenue primarily from the sale of its HEPZATO KIT in the United States and the CHEMOSAT system in Europe. The company states it has sufficient raw material and component parts to meet anticipated demand and manages supply chain risk through stockpiled inventory, as well as by contracting with multiple suppliers for critical components. Since March 1, 2022, Delcath has assumed direct responsibility for sales, marketing, and distribution of CHEMOSAT in Europe. The company also provides training, as well as support services, to hospitals and cancer centers that use its products.

The company operates through the following segments:

• Single Operating Segment: The company's single operating segment includes the development, manufacturing, and commercialization of the HEPZATO KIT drug/device combination, as well as the CHEMOSAT hepatic delivery system, for percutaneous hepatic perfusion procedures aimed at treating primary and metastatic liver cancers.

Delcath Systems, Inc. competes in the interventional oncology market against surgical resection, liver transplant, systemic chemotherapy, and other locoregional therapies such as transarterial chemoembolization and radioembolization. In the specific indication of uveal melanoma liver metastases, the company faces competition from the approved drug KIMMTRAK. It also faces competition from emerging therapies from IDEAYA Biosciences, as well as from Replimune Group. Additionally, competitors such as Boston Scientific Corporation, the Covidien products division of Medtronic plc, Merit Medical Systems, Inc., Varian Medical Systems, Inc., Sirtex Medical Limited, and AngioDynamics, Inc. offer devices for transarterial chemoembolization and radioembolization procedures. Delcath's competitive advantages include the ability to treat the entire liver, including radiologically invisible micrometastases, the repeatability of the percutaneous hepatic perfusion procedure, and six orphan drug designations that provide market exclusivity.

Delcath Systems, Inc. serves hospitals and cancer centers in the United States and Europe that perform percutaneous hepatic perfusion procedures. In the United States, the company reported 32 sites accepting referrals with 25 active sites as of December 31, 2025. In Europe, CHEMOSAT is available in 22 cancer centers across the region.

Investment Thesis

▲ Bull case

DCTH's core growth driver remains the increasing volume per activated site, which is being significantly bolstered by the widespread clinical adoption of the CHOPIN protocol (HEPZATO combined with immunotherapy) as evidenced by physician testimonials like Dr. Padia's at the Kurinsight webinar and the company's observation that most new sites are planning to implement this combination approach from inception. This trend is not merely incremental but represents a fundamental shift in treatment paradigms for metastatic uveal melanoma, directly translating to higher revenue per site and accelerating the path to profitability despite a tempered site activation target of 37 centers by year-end 2026. The strong first-quarter patient start rate of approximately 0.7 new patients per site per month, matching or exceeding prior-year levels, indicates that the commercial infrastructure is effectively converting interest into billable treatments, and this momentum is expected to compound as referral networks mature and more centers achieve full operational capacity with backup treatment teams to mitigate seasonal disruptions.
Beyond the established mUM indication, DCTH is strategically positioning itself to capture value from its clinical trials in metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC), with the company on track to activate nearly all 26 targeted mCRC trial sites by year-end 2026 and targeting 15 mBC sites by late 2026, driven by specialized training and streamlined onboarding processes that are overcoming initial enrollment headwinds. The initiation of investigator-sponsored trials presented at ASCO 2026—specifically the sequential HEPZATO followed by tebentafusp trial for mUM and the PHP plus nivolumab/relatlimab trial for metastatic non-uveal melanoma—represents a critical, underappreciated catalyst, as these studies are designed to generate pivotal data on combining HEPZATO with next-generation immunotherapies in first-line settings, potentially expanding the addressable patient population far beyond the current heavily pretreated mUM cohort and creating a pathway for label expansions that could dramatically increase the total addressable market.
Financially, DCTH is demonstrating disciplined capital allocation and operational leverage, having repurchased $9 million of its common stock under the approved $25 million buyback program while maintaining a fortress balance sheet with $89.3 million in cash and investments and zero debt, providing substantial flexibility to weather commercial execution risks or fund strategic opportunities without dilution. The company's guidance for at least $100 million in total revenue for FY26, implying 20% HEPZATO kit volume growth over 2025, is viewed as deliberately conservative given the Q1 run rate already exceeds this annual floor, with management acknowledging that the assumed seasonal impact from Q3/Q4 2025 may be overly pessimistic due to ongoing efforts to train backup treatment teams at key centers—a factor that could unlock significant upside if successful, thereby driving adjusted EBITDA positivity for the remainder of the year as forecasted and establishing a foundation for sustainable profitability.

DCTH's core growth driver remains the increasing volume per activated site, which is being significantly bolstered by the widespread clinical adoption of the CHOPIN protocol (HEPZATO combined with immunotherapy) as evidenced by physician testimonials like Dr. Padia's at the Kurinsight webinar and the company's observation that most new sites are planning to implement this combination approach from inception. This trend is not merely incremental but represents a fundamental shift in treatment paradigms for metastatic uveal melanoma, directly translating to higher revenue per site and accelerating the path to profitability despite a tempered site activation target of 37 centers by year-end 2026. The strong first-quarter patient start rate of approximately 0.7 new patients per site per month, matching or exceeding prior-year levels, indicates that the commercial infrastructure is effectively converting interest into billable treatments, and this momentum is expected to compound as referral networks mature and more centers achieve full operational capacity with backup treatment teams to mitigate seasonal disruptions.
Beyond the established mUM indication, DCTH is strategically positioning itself to capture value from its clinical trials in metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC), with the company on track to activate nearly all 26 targeted mCRC trial sites by year-end 2026 and targeting 15 mBC sites by late 2026, driven by specialized training and streamlined onboarding processes that are overcoming initial enrollment headwinds. The initiation of investigator-sponsored trials presented at ASCO 2026—specifically the sequential HEPZATO followed by tebentafusp trial for mUM and the PHP plus nivolumab/relatlimab trial for metastatic non-uveal melanoma—represents a critical, underappreciated catalyst, as these studies are designed to generate pivotal data on combining HEPZATO with next-generation immunotherapies in first-line settings, potentially expanding the addressable patient population far beyond the current heavily pretreated mUM cohort and creating a pathway for label expansions that could dramatically increase the total addressable market.
Financially, DCTH is demonstrating disciplined capital allocation and operational leverage, having repurchased $9 million of its common stock under the approved $25 million buyback program while maintaining a fortress balance sheet with $89.3 million in cash and investments and zero debt, providing substantial flexibility to weather commercial execution risks or fund strategic opportunities without dilution. The company's guidance for at least $100 million in total revenue for FY26, implying 20% HEPZATO kit volume growth over 2025, is viewed as deliberately conservative given the Q1 run rate already exceeds this annual floor, with management acknowledging that the assumed seasonal impact from Q3/Q4 2025 may be overly pessimistic due to ongoing efforts to train backup treatment teams at key centers—a factor that could unlock significant upside if successful, thereby driving adjusted EBITDA positivity for the remainder of the year as forecasted and establishing a foundation for sustainable profitability.

▼ Bear case

DCTH's commercial progress remains highly dependent on the slow and unpredictable pace of REMS-certified center activations, with management explicitly reducing its year-end 2026 activated center guidance to 37 (from a previously higher target) due to a lack of visible readiness in the pipeline, citing the necessity of having scheduled patients or screened candidates before committing to near-term activations—a process that can take over a year in some cases and introduces significant variability into revenue forecasting, as the business model relies on achieving critical mass in center count to drive meaningful volume growth, and any further delays in site readiness would directly undermine the thesis that increased utilization per site can fully offset slower expansion.
The company's clinical development pipeline, while presented as a long-term growth avenue, faces substantial hurdles that are not being adequately addressed in public communications, including the glacial enrollment pace in the metastatic colorectal cancer trial (only 7 patients enrolled across 13 active sites after significant investment) and the metastatic breast cancer trial, where real-world European data showed a median of only one treatment cycle administered—far below the protocol-specified two cycles—indicating either limited physician comfort with the procedure in this population or rapid patient deterioration due to heavy pretreatment, both of which suggest that achieving clinically meaningful efficacy signals in these trials may take considerably longer than the guided timeline for interim results in late 2027, thereby delaying any potential near-term value inflection from label expansions.
A significant and underdiscussed risk lies in the reimbursement and market access challenges outside the United States, particularly in Europe, where the CHEMOSAT device operates under a breakeven model and management concedes that European growth is significantly hampered by reimbursement issues, with expectations limited to modest single-digit growth for FY26 despite the publication of CHOPIN data in ESMO guidelines; this undermines the narrative of Europe as a key data-generation engine for future indications, as the lack of commercial traction and pricing power in these markets reduces the likelihood of generating robust, practice-changing data from European sites that could support broader global adoption or label expansions, effectively confining the company's near-term revenue potential to the U.S. market and increasing reliance on domestic execution alone.

DCTH's commercial progress remains highly dependent on the slow and unpredictable pace of REMS-certified center activations, with management explicitly reducing its year-end 2026 activated center guidance to 37 (from a previously higher target) due to a lack of visible readiness in the pipeline, citing the necessity of having scheduled patients or screened candidates before committing to near-term activations—a process that can take over a year in some cases and introduces significant variability into revenue forecasting, as the business model relies on achieving critical mass in center count to drive meaningful volume growth, and any further delays in site readiness would directly undermine the thesis that increased utilization per site can fully offset slower expansion.
The company's clinical development pipeline, while presented as a long-term growth avenue, faces substantial hurdles that are not being adequately addressed in public communications, including the glacial enrollment pace in the metastatic colorectal cancer trial (only 7 patients enrolled across 13 active sites after significant investment) and the metastatic breast cancer trial, where real-world European data showed a median of only one treatment cycle administered—far below the protocol-specified two cycles—indicating either limited physician comfort with the procedure in this population or rapid patient deterioration due to heavy pretreatment, both of which suggest that achieving clinically meaningful efficacy signals in these trials may take considerably longer than the guided timeline for interim results in late 2027, thereby delaying any potential near-term value inflection from label expansions.
A significant and underdiscussed risk lies in the reimbursement and market access challenges outside the United States, particularly in Europe, where the CHEMOSAT device operates under a breakeven model and management concedes that European growth is significantly hampered by reimbursement issues, with expectations limited to modest single-digit growth for FY26 despite the publication of CHOPIN data in ESMO guidelines; this undermines the narrative of Europe as a key data-generation engine for future indications, as the lack of commercial traction and pricing power in these markets reduces the likelihood of generating robust, practice-changing data from European sites that could support broader global adoption or label expansions, effectively confining the company's near-term revenue potential to the U.S. market and increasing reliance on domestic execution alone.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password